

Regenerative Medicine and Advanced Therapies

Open Info Day 8 July 2016

> Charles Kessler European Commission, Brussels DG Research and Innovation






Regenerative medicine and advanced therapies

Programme for this afternoon:

- Introduction and forthcoming calls
- Experiences, pitfalls to avoid and wise words (2 speakers)
- Discussion



ATMP development: targeting different points on the innovation chain





Regenerative medicine and advanced therapies

Two topics open in forthcoming calls for proposals...





1. Clinical research on regenerative medicine

Main points

- SC1-PM11-2016-2017
- Clinical research any stage; proof of regulatory engagement/autorisation
- Collaborative research min 3 EU/assoc countries
- Indicative budget: €30 million (2017)
- ~ €4-6 million per project depending on work
- Deadline: 11 April 2017





Clinical research on regenerative medicine – results so far

		Proposals		Success rate	Budget
	Received	Eligible	Supported	%	€ million
2014	30	30	6	20	35.2
2015	48	46	7	15	39.1
2016	32	30	?	?	30.0
2017	?	?	?	?	30.0

Clinical research on regenerative medicine (2014 – 2015)

		7.3 · 10i-
Project Acronym	Area covered/Condition	Approach/Technology Allogeneic Treg lymphocytes
TREGeneration	GvHD (chronic)	Allogeneic Treg lymphocytes
RETHRIM	GvHD (acute)	Allogeneic MSC (bone marrow-derived)
SCIENCE	Ischemic heart disease	Allogeneic adipose-derived MSC
ADIPOA2	Osteoarthritis	Autologous adipose-derived MSC
SC0806	Spinal cord injury	Recombinant growth factor + device
ARISE	Heart valve	Allogeneic decellularized aortic valve
NISCI	Spinal cord injury	Antibodies against Nogo-A
BOOSTB4	Osteogenesis imperfecta	Allogeneic MSC (fetal-derived)
RESSTORE	Stroke	Allogeneic adipose-derived MSC
SEPCELL	Sepsis	Allogeneic adipose-derived MSC
TETRA	Trachea (severe airway disease)	Autologous MSC + decellularized trachea scaffold
BetaCellTherapy	Type-1 diabetes	Encapsulated progenitor cells (hESC-derived)
BIO-CHIP	Knee cartilage injury	Autologous nasal chondrocytes

"To allow an adequate coverage in the field of regenerative medicine, proposals should take into account the projects previously funded under this topic in Horizon 2020"

European



2. Cell technologies in medical applications

Main points

- SMEInst-05-2016-2017 "Supporting innovative SMEs in the healthcare biotechnology sector"
- SME Instrument EU/Assoc SME(s) only (can subcontract)
- Phase 1 Feasibility study (€50,000 lump sum)
- Phase 2 Research/Innovation (~€1-5 million depending on work – 100% reimbursement)
- Indicative budget:
 - 2016: €35 million
 - 2017: €80 million (includes biomarkers and diagnostic medical devices, Phase 2, first cut-off)
- Multiple deadlines





3. Other topics that might support regenerative medicine and advanced therapies

SC1 Two-stage call - stage 1 closing 4 October 2016

- SC1-PM-02-2017 "New concepts in patient stratification"
- SC1-PM-08-2017 "New therapies for rare diseases" [read texts carefully]

Others


ERC, FET, Marie Skłodowska-Curie actions...



PARTICIPANT PORTAL Unique entry point

http://ec.europa.eu/research/participants/portal

Information available on the participant portal includes all you have to know about our programmes and about submitting a proposal





New evaluators weclome





Thank you for your attention

Charles.Kessler@ec.europa.eu

